Provided by Tiger Trade Technology Pte. Ltd.

Atrium Therapeutics

13.98
+0.36002.64%
Volume:107.45K
Turnover:1.48M
Market Cap:239.14M
PE:-3.62
High:14.01
Open:13.72
Low:13.41
Close:13.62
52wk High:16.77
52wk Low:11.13
Shares:17.11M
Float Shares:15.72M
Volume Ratio:0.65
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8578
EPS(LYR):-3.1905
ROE:-43.98%
ROA:-399.25%
PB:1.11
PE(LYR):-4.38

Loading ...

Circio bolsters board as it advances circular RNA gene therapy platform

TIPRANKS
·
1 hour ago

Press Release: Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and Eur40.25 Million PIPE Financing from New and Existing Investors

Dow Jones
·
Aug 24

BioNTech’s New HIV RNA Vaccine Trial: What Investors Should Watch Now

TIPRANKS
·
Aug 22

Brii Biosciences Narrows Interim Loss as HBV and RNA Pipelines Advance

TIPRANKS
·
Aug 21

Atrium Therapeutics Awards New Hire Stock Options for 11,000 Shares at $13.48 Each

Reuters
·
Aug 21

Atrium Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 21

Pharma Sector Doubles Down on AI Amid Hopes of Slashing Costs, Timelines

Reuters
·
Aug 20

One Nation staffer allegedly assaulted at major Australian show‘They were spat on. They were punched.’3 min read

7NEWS
·
Aug 17

Atrium Therapeutics Price Target Maintained with a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 15

The huge change set to reshape a beloved Australian traditionNew arenas, homes and facilities are coming to a historic precinct with a 150-year legacy.3 min read

7NEWS
·
Aug 15

Atrium Therapeutics, Inc. (RNA) Receives a Buy from Wells Fargo

TIPRANKS
·
Aug 14

Heart Drug Developer Atrium Therapeutics' Q2 Loss Widens as Expenses Rise

Reuters
·
Aug 14

Atrium Therapeutics Q2 Basic EPS USD -1.18

THOMSON REUTERS
·
Aug 14

Atrium Therapeutics Posts Investor Presentation on Precision RNA Medicines for Cardiac Disease

Reuters
·
Aug 14

Atrium Therapeutics Posts Q2 R&D Expense of $15.3 Million on Trial Prep, IND-Enabling Work

Reuters
·
Aug 14

Atrium Therapeutics Q2 FY26 Net Loss Widens to $20.19 Million; Revenue Falls to $3 Million

Reuters
·
Aug 14

Atrium Therapeutics Q2 EPS $(1.18) Misses $(1.01) Estimate, Sales $3.004M Beat $2.000M Estimate

Benzinga Earnings
·
Aug 14

Atrium Therapeutics, Inc. (RNA) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Aug 14

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

THOMSON REUTERS
·
Aug 13

Atrium Therapeutics - Eligible for up to $1.35 Bln R&D Milestones, $825 Mln Commercial Milestones, Tiered Royalties

THOMSON REUTERS
·
Aug 13